We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+2.78%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.04B
AUM Growth
-$13.5M
Cap. Flow
+$810K
Cap. Flow %
0.08%
Top 10 Hldgs %
35.44%
Holding
98
New
14
Increased
36
Reduced
31
Closed
5

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$31.8M
2
DHR icon
Danaher
DHR
+$9.47M
3
EW icon
Edwards Lifesciences
EW
+$8.63M
4
ELV icon
Elevance Health
ELV
+$8.62M
5
GILD icon
Gilead Sciences
GILD
+$7.44M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$21.7M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$20.8M
3
THC icon
Tenet Healthcare
THC
+$18.2M
4
MDT icon
Medtronic
MDT
+$9.59M
5
ZBH icon
Zimmer Biomet
ZBH
+$8.91M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
26
DELISTED
Dynavax Technologies
DVAX
$13.8M 1.33%
1,232,361
+75,000
+6% +$873K
ALGN icon
27
Align Technology
ALGN
$12.3B
$13.6M 1.31%
56,500
+6,500
+13% +$1.81M
TMO icon
28
Thermo Fisher Scientific
TMO
$220B
$13.3M 1.27%
24,000
+11,000
+85% +$6.3M
DXCM icon
29
DexCom
DXCM
$32B
$13.3M 1.27%
117,000
-21,500
-16% -$2.72M
CNC icon
30
Centene
CNC
$32.5B
$13.2M 1.26%
198,482
+69,482
+54% +$5.05M
ALHC icon
31
Alignment Healthcare
ALHC
$2.98B
$12.8M 1.23%
1,641,448
-381,288
-19% -$2.49M
JAZZ icon
32
Jazz Pharmaceuticals
JAZZ
$16.7B
$12.2M 1.17%
114,000
-32,729
-22% -$3.6M
DHR icon
33
Danaher
DHR
$144B
$12.1M 1.16%
48,500
+37,500
+341% +$9.47M
COR icon
34
Cencora
COR
$61.2B
$11.6M 1.11%
51,500
+9,000
+21% +$2.08M
CYTK icon
35
Cytokinetics
CYTK
$10.4B
$10.7M 1.03%
197,515
– –
NBIX icon
36
Neurocrine Biosciences
NBIX
$16.6B
$10.4M 1%
75,555
+16,555
+28% +$2.27M
AXSM icon
37
Axsome Therapeutics
AXSM
$10.9B
$10.3M 0.99%
127,600
-16,000
-11% -$1.18M
ITCI
38
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.73M 0.93%
142,000
+4,500
+3% +$312K
PODD icon
39
Insulet
PODD
$9.79B
$9.38M 0.9%
46,500
+11,750
+34% +$2.12M
EW icon
40
Edwards Lifesciences
EW
$51.7B
$9.01M 0.86%
+97,500
New +$8.63M
MDGL icon
41
Madrigal Pharmaceuticals
MDGL
$11.8B
$7.42M 0.71%
26,500
-10,000
-27% -$2.38M
IOVA icon
42
Iovance Biotherapeutics
IOVA
$2.87B
$7.38M 0.71%
920,000
-35,000
-4% -$375K
CRL icon
43
Charles River Laboratories
CRL
$12.8B
$7.02M 0.67%
34,000
+21,300
+168% +$4.83M
INSM icon
44
Insmed
INSM
$28.6B
$6.67M 0.64%
+99,513
New +$3.86M
IQV icon
45
IQVIA
IQV
$39.3B
$6.55M 0.63%
31,000
– –
NUVL
46
DELISTED
Nuvalent
NUVL
$6.28M 0.6%
82,750
-4,750
-5% -$338K
IONS icon
47
Ionis Pharmaceuticals
IONS
$9.4B
$6.2M 0.59%
+130,000
New +$5.33M
EXAS
48
DELISTED
Exact Sciences
EXAS
$6.13M 0.59%
145,000
+2,000
+1% +$110K
SYK icon
49
Stryker
SYK
$130B
$6.12M 0.59%
18,000
+10,000
+125% +$3.39M
ARVN icon
50
Arvinas
ARVN
$572M
$6.12M 0.59%
230,000
+60,000
+35% +$1.91M
1
2
3 4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Rhenman & Partners Asset Management held 98 positions worth $1.04B, down 1.3% from $1.06B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management's Q2 2024 filing shows 14 new, 36 increased, 31 reduced and 5 closed positions. Its largest new stake was Edwards Lifesciences: 97,500 shares worth $9.01M. The largest sale was Cigna, an estimated $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q2 2024 buy was Edwards Lifesciences: 97,500 shares worth $9.01M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2024, an estimated $31.8M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2024 reduction was Cigna, cutting an estimated $21.7M.
  • Rhenman & Partners Asset Management fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $20.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $1.04B portfolio in Q2 2024.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 5 in Q2 2024.
  • Rhenman & Partners Asset Management's portfolio value fell 1.3% quarter-over-quarter to $1.04B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.